New Drug Approval Process, Fifth Edition

550 Pages·2009·4.18 MB·English

by  Guarino

DPS_6x9_Generic_Walsworth.indd
Pharmaceutical Science and technology 190 DRUGS AND THE PHARMACEUTICAL SCIENCES VOLUME 190
about the book…
F iFt h E d i t i o n
The thoroughly revised Fifth Edition of New Drug Approval Process
FiFth
supplies readers with the latest global changes that affect pharmaceutical
product approval and influence how new products are researched and Edition
marketed.
New Drug
Updated chapters include:
• advances in international regulatory requirements, including ICH
guidelines and harmonization N
• a step-by-step format for content, assembly, and strategic approach e
in filing US and global INDs, IMPDs, NDAs, BLAs, ANDAs, and SNDAs w Approval Process
in the CTD format
D
• the latest regulatory requirements for expediting new drug approvals
r
• strategies for effective communication and integration of u S:
E
pharmaceutical personnel in all aspects of new drug development g T
O
N
about the editor... A XX
p X
RICHARD A. GUARINO is President, Oxford Pharmaceutical Resources, pr GCP GMP D: X
GLP E
Inc., Totowa, New Jersey, USA. Dr. Guarino has 25 years of experience in o S
VI
new drug applications, marketing launches, advertising, and FDA liaison. v IND RE
He is former President and CEO of Oxford Research International Corp.; a E
former Director of Clinical Research at Sandoz Pharmaceutical Inc. (now l P BLA X DAT
Novartis); and former Vice President/Medical Director at Revlon Healthcare r X
X
Group. Dr. Guarino is a member of many professional societies and o IMPD XX
associations including the Royal Society of Medicine, the Association c D:
e 510K E
T
of Clinical Research Professionals, and the Academy of Pharmaceutical s A
E
Physicians and Investigators, among others. s CTD CR
E
Printed in the United States of America ANDA NDA AT
D
SNDA X
X
X
X
Guarino E: X
M
A
H8849 N
edited by E
L
FI
Richard A. Guarino, M.D. X
X
R:
E
N
G
SI
E
D
Guarino_978-1420088496.indd 1 6/3/09 2:01:52 PM
PANTONE 202 C
New Drug
Approval Process
Guarino_978-1420088496_TP.indd 1 6/3/09 2:01:26 PM
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
DRUGS AND THE PHARMACEUTICAL SCIENCES
ASeriesofTextbooksandMonographs
ExecutiveEditor
JamesSwarbrick
PharmaceuTech,Inc.
Pinehurst,NorthCarolina
AdvisoryBoard
LarryL.Augsburger HarryG.Brittain
UniversityofMaryland CenterforPharmaceuticalPhysics
Baltimore,Maryland Milford,NewJersey
JenniferB.Dressman RobertGurny
UniversityofFrankfurtInstituteof UniversitedeGeneve
PharmaceuticalTechnology Geneve,Switzerland
Frankfurt,Germany
JeffreyA.Hughes
AnthonyJ.Hickey UniversityofFloridaCollege
UniversityofNorthCarolina ofPharmacy
SchoolofPharmacy Gainesville,Florida
ChapelHill,NorthCarolina
VincentH.L.Lee
AjazHussain USFDACenterforDrug
Sandoz EvaluationandResearch
Princeton,NewJersey LosAngeles,California
JosephW.Polli KinamPark
GlaxoSmithKline PurdueUniversity
ResearchTrianglePark WestLafayette,Indiana
NorthCarolina
JeromeP.Skelly
StephenG.Schulman Alexandria,Virginia
UniversityofFlorida
Gainesville,Florida ElizabethM.Topp
UniversityofKansas
YuichiSugiyama Lawrence,Kansas
UniversityofTokyo,Tokyo,Japan
PeterYork
GeoffreyT.Tucker UniversityofBradford
UniversityofSheffield SchoolofPharmacy
RoyalHallamshireHospital Bradford,UnitedKingdom
Sheffield,UnitedKingdom
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
ForInformationonvolumes1–149intheDrugsandPharmaceuticalScienceSeries,
Pleasevisitwww.informahealthcare.com
150. LaboratoryAuditingforQualityandRegulatoryCompliance,DonaldSinger,
Raluca-loanaStefan,andJacobusvanStaden
151. ActivePharmaceuticalIngredients:Development,Manufacturing,andRegulation,
editedbyStanleyNusim
152. PreclinicalDrugDevelopment,editedbyMarkC.RoggeandDavidR.Taft
153. PharmaceuticalStressTesting:PredictingDrugDegradation,editedbyStevenW.
Baertschi
154. HandbookofPharmaceuticalGranulationTechnology:SecondEdition,editedby
DilipM.Parikh
155. PercutaneousAbsorption:Drugs–Cosmetics–Mechanisms–Methodology,Fourth
Edition,editedbyRobertL.BronaughandHowardI.Maibach
156. Pharmacogenomics:SecondEdition,editedbyWernerKalow,UrsA.Meyerand
RachelF.Tyndale
157. PharmaceuticalProcessScale-Up,SecondEdition,editedbyMichaelLevin
158. Microencapsulation:MethodsandIndustrialApplications,SecondEdition,edited
bySimonBenita
159. NanoparticleTechnologyforDrugDelivery,editedbyRamB.GuptaandUdayB.
Kompella
160. SpectroscopyofPharmaceuticalSolids,editedbyHarryG.Brittain
161. DoseOptimizationinDrugDevelopment,editedbyRajeshKrishna
162. HerbalSupplements-DrugInteractions:ScientificandRegulatoryPerspectives,
editedbyY.W.FrancisLam,Shiew-MeiHuang,andStephenD.Hall
163. PharmaceuticalPhotostabilityandStabilizationTechnology,editedbyJosephT.
PiechockiandKarlThoma
164. EnvironmentalMonitoringforCleanroomsandControlledEnvironments,editedby
AnneMarieDixon
165. PharmaceuticalProductDevelopment:InVitro-lnVivoCorrelation,editedby
DakshinaMurthyChilukuri,GangadharSunkara,andDavidYoung
166. NanoparticulateDrugDeliverySystems,editedbyDeepakThassu,Michel
Deleers,andYashwantPathak
167. Endotoxins:Pyrogens,LALTestingandDepyrogenation,ThirdEdition,editedby
KevinL.Williams
168. GoodLaboratoryPracticeRegulations,FourthEdition,editedbyAnneSandy
Weinberg
169. GoodManufacturingPracticesforPharmaceuticals,SixthEdition,editedby
JosephD.Nally
170. Oral-LipidBasedFormulations:EnhancingtheBioavailabilityofPoorly
Water-solubleDrugs,editedbyDavidJ.Hauss
171. HandbookofBioequivalenceTesting,editedbySarfarazK.Niazi
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
172. AdvancedDrugFormulationDesigntoOptimizeTherapeuticOutcomes,editedby
RobertO.WilliamsIII,DavidR.Taft,andJasonT.McConville
173. Clean-in-PlaceforBiopharmaceuticalProcesses,editedbyDaleA.Seiberling
174. FiltrationandPurificationintheBiopharmaceuticalIndustry,SecondEdition,
editedbyMaikW.JornitzandTheodoreH.Meltzer
175. ProteinFormulationandDelivery,SecondEdition,editedbyEugeneJ.McNally
andJayneE.Hastedt
176. AqueousPolymericCoatingsforPharmaceuticalDosageForms,ThirdEdition,
editedbyJamesMcGinityandLindaA.Felton
177. DermalAbsorptionandToxicityAssessment,SecondEdition,editedbyMichaelS.
RobertsandKennethA.Walters
178. PreformulationSolidDosageFormDevelopment,editedbyMojiC.Adeyeyeand
HarryG.Brittain
179. Drug-DrugInteractions,SecondEdition,editedbyA.DavidRodrigues
180. GenericDrugProductDevelopment:BioequivalenceIssues,editedbyIsadore
KanferandLeonShargel
181. PharmaceuticalPre-ApprovalInspections:AGuidetoRegulatorySuccess,
SecondEdition,editedbyMartinD.HynesIII
182. PharmaceuticalProjectManagement,SecondEdition,editedbyAnthonyKennedy
183. ModifiedReleaseDrugDeliveryTechnology,SecondEdition,Volume1,editedby
MichaelJ.Rathbone,JonathanHadgraft,MichaelS.Roberts,andMajellaE.Lane
184. Modified-ReleaseDrugDeliveryTechnology,SecondEdition,Volume2,editedby
MichaelJ.Rathbone,JonathanHadgraft,MichaelS.Roberts,andMajellaE.Lane
185. ThePharmaceuticalRegulatoryProcess,SecondEdition,editedbyIraR.Berry
andRobertP.Martin
186. HandbookofDrugMetabolism,SecondEdition,editedbyPaulG.Pearsonand
LarryC.Wienkers
187. PreclinicalDrugDevelopment,SecondEdition,editedbyMarkRoggeandDavid
R.Taft
188. ModernPharmaceutics,FifthEdition,Volume1:BasicPrinciplesandSystems,
editedbyAlexanderT.FlorenceandJu¨rgenSiepmann
189. ModernPharmaceutics,FifthEdition,Volume2:ApplicationsandAdvances,
editedbyAlexanderT.FlorenceandJu¨rgenSiepmann
190. NewDrugApprovalProcess,FifthEditioneditedbyRichardA.Guarino
F iFt h E d i t i o n
New Drug
Approval Process
edited by
Richard A. Guarino, M.D.
Oxford Pharmaceutical Resources, Inc.
Totowa, New Jersey, USA
Guarino_978-1420088496_TP.indd 2 6/3/09 2:01:27 PM
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
InformaHealthcareUSA,Inc.
52VanderbiltAvenue
NewYork,NY10017
(cid:1)C 2009byInformaHealthcareUSA,Inc.
InformaHealthcareisanInformabusiness
NoclaimtooriginalU.S.Governmentworks
PrintedintheUnitedStatesofAmericaonacid-freepaper
10987654321
InternationalStandardBookNumber-10:1-4200-8849-1(Hardcover)
InternationalStandardBookNumber-13:978-1-4200-8849-6(Hardcover)
Thisbookcontainsinformationobtainedfromauthenticandhighlyregardedsources.Reprinted
materialis quotedwithpermission, and sources areindicated. A widevarietyofreferences are
listed.Reasonableeffortshavebeenmadetopublishreliabledataandinformation,buttheauthor
andthepublishercannotassumeresponsibilityforthevalidityofallmaterialsorfortheconse-
quenceoftheiruse.
Nopartofthisbookmaybereprinted,reproduced,transmitted,orutilizedinanyformbyany
electronic,mechanical,orothermeans,nowknownorhereafterinvented,includingphotocopying,
microfilming, and recording, or in any information storage or retrieval system, without written
permissionfromthepublishers.
For permission to photocopy or use material electronically from this work, please access
www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center,
Inc.(CCC)222RosewoodDrive,Danvers,MA01923,978-750-8400.CCCisanot-for-profitorga-
nizationthatprovideslicensesandregistrationforavarietyofusers.Fororganizationsthathave
beengrantedaphotocopylicensebytheCCC,aseparatesystemofpaymenthasbeenarranged.
TrademarkNotice:Productorcorporatenamesmaybetrademarksorregisteredtrademarks,and
areusedonlyforidentificationandexplanationwithoutintenttoinfringe.
LibraryofCongressCataloging-in-PublicationData
Newdrugapprovalprocess/editedbyRichardA.Guarino.–5thed.
p.;cm.–(Drugsandthepharmaceuticalsciences;190)
Includesbibliographicalreferencesandindex.
ISBN-13:978-1-4200-8849-6(hardcover:alk.paper)
ISBN-10:1-4200-8849-1(hardcover:alk.paper)1.Drugapproval–United
States. 2.Drugs–Testing–Standards. 3.Drugs–Testing–Gevernment
policy–UnitedStates. 4.Newproducts–Governmentpolicy–UnitedStates.
I.Guarino,RichardA.,1935-II.Series:Drugsandthepharmaceuticalsciences;
v.190.
[DNLM:1.DrugEvaluation–standards–UnitedStates. 2.ClinicalTrialsas
Topic–standards–UnitedStates. 3.DrugApproval–UnitedStates.
W1DR893Bv.1902009/QV771N53182009]
RS189.N4762009
615’.1–dc22
2009007532
ForCorporateSalesandReprintPermissionscall212-520-2700orwriteto:SalesDepartment,
52VanderbiltAvenue,16thfloor,NewYork,NY10017.
VisittheInformaWebsiteat
www.informa.com
andtheInformaHealthcareWebsiteat
www.informahealthcare.com
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
Mysinceregratitudegoestoourarmedforcesandmyfamilymemberswhosacrificetheir
livestoprotectournation’sfreedomandtheprinciplesthatmakeAmericaaworldleaderin
givingmankindequalrightsintheirpursuitofendeavors.
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
SPH SPH
fm IHBK037-Guarino May7,2009 7:59 CharCount=
Preface
Globalregistrationofpharmaceuticaldrug,biologic,anddeviceproductsisnowthe
way pharmaceutical development and marketing are strategically planned. Since
thepublicationofthefourtheditionofNewDrugApprovalProcess,therehavebeen
manychangesintheregulations,requirements,andrecommendationsforinterna-
tionalregistrationandapprovalofnewproducts.
NewDrugApprovalProcess,FifthEditionoffers,indetail,thenecessaryandvital
information on how to develop and submit the research and the documentation
requiredbyworldwideagenciestoobtainnewpharmaceuticalproductapprovals.
The topics include a comprehensive as well as a pragmatic approach in address-
ingallaspectsofclinicalresearchdevelopmentincludingstatisticalmethodologies,
global regulatory requirements for pharmaceutical product applications, and the
mechanicsnecessarytounderstandandimplementGoodClinicalPractices(GCP),
GoodLaboratoryPractices(GLP),andGoodManufacturingPractices(GMP).
Each contributing author is an expert in their respective field and has the
knowledgeandexperiencetoeducatethereadersonthetechnicalaswellasthereg-
ulatoryrequirementsforeachtopicpresented.Inaddition,theyalsogiveapractical
approachtoresolveproblemsthatmightoccurduringproductdevelopment.They
imparttheiryearsofsuccessesandfailuresinawaythatthereaderscantakeadvan-
tage of this information and apply it to their research practices and job descrip-
tions,andcanhaveaclearunderstandingofthescientificandlegalresponsibilities
requiredtobringnewpharmaceuticalproductstomarket.
The approach and format for assembling the specific data necessary to gain
new product approvals globally have drastically changed in the past four years.
The Investigational New Drug (IND) Application is still well accepted by the US
FDAandwillsoonrequireto besubmittedinelectronicform.Thesameinforma-
tion,duetotheimplementationoftheEuropeanDirectives,isnowexpectedinthe
countriesbelongingtotheEuropeanUnionandiscontainedinanInvestigational
MedicinalProductDossier(IMPD).TheNewDrugApplication(NDA)information
is now in the format of the Common Technical Document (CTD) and is submit-
ted to the regulatory agencies electronically termed an eCTD. These submissions
as well as Biologic License Applications (BLAs), Abbreviated New Drug Appli-
cations (ANDAs), Supplemental New Drug Applications (SNDAs), and 505(b)(2)
Applicationsaredetailed.Inaddition,theessentialcomponentsofthenonandpre-
clinicalandclinicaldevelopmentcomprisingthesafetyandefficacyofproductsare
presented and are integrated with the regulatory requirements necessary to expe-
ditenewproductapprovals.TheChemistry,Manufacturing,andControls(CMC),
ix